author-photo

Roger M. Lyons

Texas Oncology
University of Texas at San Antonio

142

Papers

7105

Citations

Citation Trend

Filter By

Papers (142) Sort By

Journal Conference Others

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Disease and Clinical Characteristics of Patients With A Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Drug shows the potential for long-term relief from a type of chronic leukemia

2021
Show All
- Source
- Cite
- Save
Citations (0)
Real-World Patterns of Molecular Genetic Testing Among Patients with Acute Myeloid Leukemia in US Community Oncology Settings

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
AML-059: Treatment Outcomes and Healthcare Resource Utilization (HRU) Among Patients with Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in US Community Oncology Setting

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Treatment outcomes and healthcare resource utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)